Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Blood (2018) 132 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2018-99-115725

Published: 2018

Journal Articles

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Blood (2016) 128 (22): 2954.

https://doi.org/10.1182/blood.V128.22.2954.2954

Published: 2016

Journal Articles

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Maria Roussou, Evdoxia Hadjiharissi, Argyris Symeonidis, Panagiotis Repoussis, Evridiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2015) 126 (11): 1392–1394.

https://doi.org/10.1182/blood-2015-05-647420

Published: 2015

Includes: Supplemental data

Journal Articles

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

Blood (2013) 122 (21): 4084.

https://doi.org/10.1182/blood.V122.21.4084.4084

Published: 2013

Journal Articles

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Blood (2013) 122 (21): 1866.

https://doi.org/10.1182/blood.V122.21.1866.1866

Published: 2013

Journal Articles

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years

Efstathios Kastritis, Marie-Christine Kyrtsonis, MD, Evdoxia Hatjiharissi, Argiris S. Symeonidis, Amalia Vassou, Panagiotis Repousis, Sosana Delimpasi, Anastasia Sioni, Eurydiki Michalis, Michalis Michael, Elina Vervessou, Ekaterini Stefanoudaki, Michael Voulgarelis, Costas Tsatalas, Evangelos Terpos, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3197.

https://doi.org/10.1182/blood.V122.21.3197.3197

Published: 2013

Journal Articles

Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents

Argiris S. Symeonidis, Efstathios Kastritis, Sosana Delimpasi, Charikleia Kelaidi, Anastasia Sioni, Michalis Michael, Amalia Vassou, Anna Christoforidou, Panagiotis Repousis, Eudokia M. Mandala, Evangelos Terpos, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3226.

https://doi.org/10.1182/blood.V122.21.3226.3226

Published: 2013

Journal Articles

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Meletios A. Dimopoulos, MD, Maria Roussou, Efstathios Kastritis, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, MD, PhD, Panagiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas

Blood (2012) 120 (21): 438.

https://doi.org/10.1182/blood.V120.21.438.438

Published: 2012

Journal Articles

BIK (Bcl2-Interacting Killer) CpG Methylation Status in Multiple Myeloma Patients: a Potential Predictor of Relapsed/Refractory Disease.

Eleftheria Hatzimichael, Aggeliki Dasoula, George Dranitsaris, Amalia Vassou, Justin Stebbing, Tim Crook, Konstantinos Bourantas

Blood (2009) 114 (22): 2397.

https://doi.org/10.1182/blood.V114.22.2397.2397

Published: 2009

Journal Articles

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study.

Meletios A. Dimopoulos, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, Panayiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Costas Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Nikolaos Anagnostopoulos, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas

Blood (2009) 114 (22): 2887.

https://doi.org/10.1182/blood.V114.22.2887.2887

Published: 2009

Journal Articles

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).

Athanasios Anagnostopoulos, MD, Lia A. Moulopoulos, M.D., Maria Roussou, M.D., Efstathios Kastritis, M.D., Dimitra Gika, George Bozas, M.D., Aikaterini Stefanoudaki, M.D., Nikolaos Anagnostopoulos, M.D., Amalia Vassou, M.D., Konstantinos Bourantas, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 3095.

https://doi.org/10.1182/blood.V108.11.3095.3095

Published: 2006

Journal Articles

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Athanasios Anagnostopoulos, MD, Steven P. Treon, MD, Konstantinos Zervas, MD, Andrew Branagan, MD, Dimitra Gika, Athanasios Zomas, MD, Marie Christine Kyrtsonis, MD, Amalia Vassou, MD, Nikolaos Anagnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3485.

https://doi.org/10.1182/blood.V106.11.3485.3485

Published: 2005

Journal Articles

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Meletios A. Dimopoulos, MD, Panagiotis Repoussis, MD, Evangelos Terpos, MD, Maria Christina Kyrtsonis, MD, Athanasios Zomas, MD, Eirini Katodritou, MD, Souzana Delibasi, MD, Amalia Vassou, MD, Athanasios Anagnostopoulos, MD, Anastasia Pouli, MD, Konstantinos Zervas, MD, Dimitrios Margaritis, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD

Blood (2004) 104 (11): 1482.

https://doi.org/10.1182/blood.V104.11.1482.1482

Published: 2004

NARROW

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years

Multiple Myeloma Patients ≤40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

BIK (Bcl2-Interacting Killer) CpG Methylation Status in Multiple Myeloma Patients: a Potential Predictor of Relapsed/Refractory Disease.

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study.

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only